This meeting marks one year since the approval of the first oral immunotherapy product for food allergy. Much of the early experience was inhibited by the coronavirus pandemic. We have the opportunity now to review current experience, discuss the ideal office approach, and also to inform the allergist about the next group of foods for which oral immunotherapy is likely.

Upon completion of this activity, participants should be able to:

  • Describe options for oral immunotherapy
  • Identify the ideal patient for oral immunotherapy
  • List potential allergens in the pipeline for therapy


Anna Nowak-Wegrzyn, MD PhD
NYU Langone Health

Rachel Story, MD MPH
NorthShore University Health Systems

Brian Vickery, MD FAAAAI
Emory University